CRISPR Therapeutics to Present Clinical Data from Zugo-cel in Large B-Cell Lymphoma at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition

ZUG, Switzerland and BOSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that clinical data in patients with relapsed or refractory large B-cell lymphoma from the ongoing Phase 1/2 trial of zugocabtagene geleucel (zugo-cel), its investigational allogeneic CRISPR/Cas9 gene-edited chimeric antigen receptor (CAR) T cell therapy targeting CD19, will be presented in an oral presentation at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 12 to 15, 2026.

Abstract Title: Zugocabtagene geleucel (zugo-cel), an off-the-shelf CRISPR-Cas9 engineered CD19 CAR T cell therapy demonstrates dose-dependent efficacy in highly refractory large B-cell lymphoma Abstract Number: 706 Session Type: Oral Presentation Session Title: 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Next-Generation CAR T-Cell Therapy in Lymphoma: In Vivo Engineering and Beyond Session Date and Time: Sunday, December 13, 2026, 5:15 p.m. CST